Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease

Drugs and Aging

Volumn 9, Issue 3, 1996, Pages 149-158

  Henry, Brian ^a   Brotchie, Jonathan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APOMORPHINE; BROMOCRIPTINE; CYPRODIME; DELTA OPIATE RECEPTOR; DYNORPHIN; ENKEPHALIN; KAPPA OPIATE RECEPTOR; LEVODOPA; LISURIDE; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE; OPIATE ANTAGONIST; PEPTIDE;

BASAL GANGLION; DYSKINESIA; GLOBUS PALLIDUS; HUMAN; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PEPTIDE SYNTHESIS; PEPTIDERGIC NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0029762313     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609030-00001     Document Type: Review

References (66)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden C, Fahn S, editors. Movement disorders. London: Butterworth Scientific, 1982: 96-122
2. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969; 280: 337-45
3. Yhar MD, Duvosin RC, Schear MJ, et al. Treatment of parkinsonism with L-dopa. Arch Neurol 1969; 280: 343-54
4. Barbeau A. L-dopa therapy in Parkinson's disease - a critical review of nine years experience. Can Med Assoc J 1969; 101: 791-800
5. Marsden CD, Parkes JD. 'On-off effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1: 292-6
6. Barbeau A. The clinical physiology of side effects in long-term L-dopa therapy. Adv Neurol 1974; 5: 347-65
7. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa in Parkinson's disease. Q J Med 1980; 49: 283-93
8. Barbeau A. High-level levodopa therapy in severely akinetic parkinsonism patients: twelve years later. In: Rinne VK, Klinger M, Stamm G, editors. Parkinson's disease: current progress, problems and management. Amsterdam: Elsevier, 1980: 229-39
9. Nutt JG. Levodopa-induced dyskinesia. Neurology 1990; 40: 340-5
10. Crossman AR. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987; 21: 1-40
11. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa - or dopamine agonist-induced dyskinesias in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990; 5 (2): 100-8
12. Mitchell IJ, Jackson A, Sambrook MA, et al. Common neural mechanisms in experimental chorea and hemiballismus in the monkey: evidence from 2-deoxyglucose autoradiography. Brain Res 1985; 339: 346-50
13. Burton K, Calne DB. Dopamine agonists and Parkinson's disease. Clin Neurol Neurosurg 1984; 86 (3): 172-7
14. Le Witt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33: 1009-14
15. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9 (4): 431-6
16. Rabey JM, Nissipeanu P, Inzelberg R. Beneficial effects of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease. Clin Neurol 1994; 17 (3): 286-93
17. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989; 39: 336-9
18. Lieberman A, Kupersmith M, Estey E, et al. Treatment of Parkinson's disease with bromocriptine. N Engl J Med 1976; 295 (25): 1400-4
19. Bedard PJ, Di Paolo T, Falardeau P, et al. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys: correlation with [3H]spiperone binding. Brain Res 1986; 379: 294-9
20. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981; 44: 1020-3
21. Calne DB, Teychenne PF, Claveria LF, et al. Bromocriptine in parkinsonism. BMJ 1974; 4: 442-4
22. Parkes JD, Debono AG, Marsden CD. Bromocriptine in parkinsonism: long-term treatment dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry 1976; 39: 1101-8
23. Kartzinel R, Teychenne P, Gillespie MM, et al. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet 1976 Aug 7; II: 272-5
24. Lees AJ. Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993; 307: 469-72
25. Calne DB, Plotkin C, Williams AC, et al. Long-term treatment of parkinsonism with bromocriptine. Lancet 1978 Apr 8; I: 735-7
26. Hoehn MM. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta Neurol Scand 1985; 71: 97-106
27. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987; 37: 826-8
28. Tolosa ES, Martin WE, Cohen HP, et al. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology 1975; 25: 177-83
29. Tolosa ES, Martin WE, Cohen HP. Dyskinesias during levodopa therapy. Lancet 1975 Jun 21; I: 1381-2
30. Muenter MD, Sharpless NS, Tyce GM, et al. Patterns of dystonia ('I-D-I' and 'D-I-D') in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977; 52: 163-74
31. Tolosa E, Alom J. Drug-induced dyskinesias. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Urban and Schwarzenberg, 1988: 327-47
32. Martin JP. Hemichorea resulting from a local lesion of the brain (syndrome of body of Luys). Brain 1927; 50: 637-51
33. Whittier JR, Mettler FA. Studies on the subthalamus of rhesus monkey: II. Hyperkinesia and other physiological effects of subthalamic lesions, with special reference to the subthalamic nucleus of Luys. J Comp Neurol 1949; 90: 319-72
34. Hammond C, Feger J, Biolac B, et al. Experimental hemiballismus produced by unilateral kanic acid lesion in the corpus Luysii. Brain Res 1979; 191: 577-80
35. Mitchell IJ, Jackson A, Sambrook MA, et al. The role of the subthalamic nucleus in experimental chorea: evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain 1989; 112: 1533-48
36. Mitchell U, Crossman AR, Liminga U, et al. Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey. Mov Disord 1992; 7: 32-7
37. Cuello AC, Paxinos G. Evidence for a long leu-enkephalin striopallidal pathway in the rat brain. Nature 1978; 271: 178-80
38. Del Fiacco M, Paxinos G, Levanti MC. Neostriatal enkephalin immunoreactive neurons project to the globus pallidus. Brain Res 1982; 231: 1-17
39. Gerfen CG, Young III WS. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridisation histochemistry and fluorescent retrograde tracing study. Brain Res 1988; 460: 161-7
40. Vincent SR, Hokfelt T, Christensson I, et al. Immunohistochemical evidence for a dynorphinergic immunoreactive strionigral pathway. Eur J Pharmacol 1982; 85: 251-2
41. Maneuf YP, Mitchell IJ, Crossman AR, et al. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 1994; 125: 65-71
42. Maneuf YP, Mitchell IJ, Crossman AR, et al. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res 1995; 683: 102-8
43. Hill MP, Brotchie JM. Modulation of glutamate release by a κ-opioid receptor agonist in rodent and primate striatum. Eur J Pharmacol 1995; 281: R1-2
44. Hille CJ, Hill MP, Brotchie JM. Modulation of glutamate transmission in the basal ganglia by enadoline, a selective kappa-opioid receptor agonist, in the marmoset and rat. In: Ohye O, Kimura M, McKenzie J, editors. The basal ganglia V. Plenum. In press
45. Abou-Khalil B, Young AB, Penney JB. Evidence for the presynaptic localisation of opiate binding sites on striatal efferent fibres. Brain Res 1984; 323: 21-9
46. Goldstein A, Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol 1989; 36 (2): 265-72
47. Ungerstedt U. 6-hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968; 5: 107-10
48. Marsden CD, Duvoisin C, Jenner P, et al. Relationship between animal models and clinical parkinsonism. Adv Neurol 1975; 9: 165-75
49. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13 (7): 281-5
50. Waters CM, Peck R, Rossor M, et al. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience 1988; 25 (2): 419-38
51. Gerfen CR, McGinty JF, Young III WS. Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: in situ hybridisation histochemical analysis. J Neurosci 1991; 11: 1016-31
52. Engber TM, Susel Z, Kuo S, et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output neurons of 6-hydroxydopamine lesioned rats. Brain Res 1991; 552: 113-8
53. Mocchetti I, Naranjo J, Costa E. Regulation of striatal enkephalin turnover in rats receiving antagonists of specific dopamine subtypes. J Pharmacol Exp Ther 1987; 241: 1120-4
54. Young III WS, Bonner TI, Brann MR. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc Natl Acad Sci USA 1986; 83: 9827-31
55. Li SJ, Jiang HK, Stachowiak MS, et al. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum. Brain Res Mol Brain Res 1990; 8: 219-25
56. Carey RJ. Naloxone reverses L-DOPA induced overstimulation effects in a Parkinson's disease animal model analogue. Life Sci 1991; 48: 1303-8
57. Henry B, Crossman AR, Brotchie JM. Opioid peptide involvement in L-DOPA-induced dyskinesias: molecular and behavioural studies following long-term treatment in the 6-OHDA-lesioned rat model of Parkinson's disease [abstract P 204]. 4th International Congress of Movement Disorders: Vienna: 1996 Jun 17-21. Mov Disord 1996; 11 Suppl. 1: 61
58. Pollock J, Kornetsky C. Naloxone prevents and blocks the emergence of neuroleptic-mediated oral stereotypic behaviors. Neuropsychopharmacology 1991; 4 (4): 245-9
59. Stoessl JA, Polanski E, Frydryszak H. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Mov Disord 1993; 8 (4): 445-52
60. Blum I, Munitz H, Shalev A, et al. Naloxone may be beneficial in the treatment of tardive dyskinesia. Clin Neuropharmacol 1984; 7 (3): 265-7
61. Lindenmayer JP, Gardner E, Goldberg E, et al. High-dose naloxone in tardive dyskinesia. Psychiatry Res 1988; 26: 19-28
62. Kurlan R, Majumdar L, Deeley C, et al. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann Neurol 1991; 30: 19-23
63. Trabucchi M, Bussi S, Frattola L. Effect of naloxone on the 'on-off' syndrome in patients receiving long-term levodopa therapy. Arch Neurol 1982; 39: 120-1
64. Sandyk R, Snider SN. Naloxone treatment of I-dopa-induced dyskinesias in Parkinson's disease [letter]. Am J Psychiatry 1986; 143 (1): 118
65. Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharm 1993; 16 (5): 418-27
66. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994; 9 (4); 437-40